Trial
NCT05059470
IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
M.D. Anderson Cancer Center
Collaborators
—
Condition
Thyroid
Intervention
Pembrolizumab
Why stopped
\<75% participant accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-03-23